Amlodipine + lisinopril

Full Generic Medicine Info
Dosage/Direction for Use

Mild to moderate hypertension
Adult: Each tablet contains amlodipine 5 mg and lisinopril 5 mg: Usual initial dose 1 tablet daily. May increase to 2 tablets daily, if BP control is still inadequate after 1-2 wk.
Hypersensitivity to either component, history of angioedema related to ACE inhibitor, patients with hereditary or idiopathic angioedema. Pregnancy & lactation.
Special Precautions
Renal impairment, hepatic impairment and heart failure. Caution when used in patients with severe obstructive coronary artery disease due to risk of increased frequency, duration and/or severity of angina or acute MI. Safety and efficacy have not been established in children.
Adverse Reactions
Nausea, headache, dizziness, cough, diarrhoea, fatigue, rash, oedema, flushing, palpitation, chest pain, asthenia, dry mouth; elevations in BUN, serum creatinine and potassium may occur.
Potentially Fatal: Angioneurotic oedema reported with ACE inhibitors.
Amlodipine: Elevate the extremities if hypotension occurs. Admin vasopressors (such as phenylpehrine) if needed. Lisinopril: Most likely manifestation of overdosage is hypotension; treat with IV infusion of normal saline solution. Can be removed by hemodialysis.
Drug Interactions
There is an increased risk of hypotension with concurrent use of antihypertensives with alprostadil. Amlodipine: Increased risk of hypotension with concurrent use with alprostadil, non-nucleoside reverse trancriptase inhibitors and cytochrome P450 inhibitors such as protease inhibitors (such as ritonovir), quinupristin/dalfopristin, azole antifungals (such as itraconazole and ketoconazole). Reduced effect of amlodipine with cytochrome P450 inducers such as phenobarbital, primidone, rifampicin and St John's Wort. Lisinopril: It reduces potassium loss caused by thiazides. Patients on diuretics may experience increased reduction in BP. Hyperkalaemia with concomitant use of potassium-sparing diuretics/potassium supplements may occur. Lisinopril may increase serum-lithium levels; monitoring of serum lithium levels is recommended. Concurrent use with NSAIDs may further worsen renal function in patients with renal impairment; may also reduce the antihypertensive effect of lisinopril.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into the vascular smooth muscle and cardiac muscle. Lisinopril is an angiotension-converting enzyme inhibitor that reduces BP, mainly by suppressing the renin-angiotensin-aldosterone system.
Absorption: Amlodipine: Plasma levels peak between 6-12 hr after oral admin; absolute bioavailability is about 64-90%. Lisinopril: Serum levels peak at approx 7 hr after oral admin.
Distribution: Amlodipine: Volume of distribution: 21L/kg; protein-binding: 93 to 98%. Lisinopril: Protein-binding: 25%
Metabolism: Amlodipine: About 90% converted to inactive metabolites by the liver. Lisinopril: Does not undergo metabolism.
Excretion: Amlodipine: 10% of the parent drug and 60% of the metabolites are removed in the urine; terminal elimination half-life of about 30-50 hr. Lisinopril: Excreted unchanged entirely in the urine; elimination half-life: 11-12 hr.
ATC Classification
C09AA03 - lisinopril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
C08CA01 - amlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on amlodipine + lisinopril from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in